Abstract: The present invention relates to a novel selenophenochromene hydroxamic acids as angiogenesis inhibitors, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment or prevention of various diseases and disorders by administration of such substances.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
August 13, 2024
Assignee:
Latvian Institute of Organic Synthesis
Inventors:
Pavels Arsenjans, Jelena Vasiljeva, Ilona Domraceva
Abstract: The present invention relates to a novel cancer metastasis preventing and curing selenopheno[h]chromene derivatives, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment and/or prevention of primary cancer and its metastasis by administration of such substances.
Abstract: Use of 2-(5S-Methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide or its pharmaceutically acceptable salt in manufacture of a medicament for prophylaxis and treatment of seizure.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
October 23, 2018
Assignee:
Latvian Institute of Organic Synthesis
Inventors:
Liga Zvejniece, Maija Dambrova, Baiba Svalbe, Edijs Vavers, Ivars Kalvins, Grigorijs Veinbergs, Ilmars Stonans, Ilga Misane, Maksims Vorona, Aleksandrs Cernobrovijs
Abstract: The invention relates to medicine, in particular S-Phenotropil ((S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide) containing pharmaceutical compositions and their use in control of body mass gain.
Type:
Application
Filed:
October 20, 2014
Publication date:
September 1, 2016
Applicant:
Latvian Institute of Organic Synthesis
Inventors:
Ivars KALVINS, Liga ZVEJNIECE, Larisa VARACEVA, Aleksandrs CERNOBROVIJS, Antons LEBEDEVS, Maija DAMBROVA, Baiba SVALBE, Edgars LIEPINS
Abstract: The invention discloses the use of pharmaceutical compositions containing 3-(2,2,2-trimethylhydrazinium)propionate dihydrate and pharmaceutically acceptable salts thereof for trimethylamine N-oxide level decrease in a body.
Type:
Application
Filed:
October 24, 2013
Publication date:
November 5, 2015
Applicant:
Latvian Institute of Organic Synthesis
Inventors:
Ivars KALVINS, Maija DAMBROVA, Edgars LIEPINS, Elina MAKAROVA, Osvalds PUGOVICS, Solveiga GRINBERGA, Eduards SEVOSTJANOVS
Abstract: The present invention provides a method for regeneration of chiral 2,2?-cyclopropylidene-bis(oxazolines), such as (3&R,3?aR,8aS,8?aS)-2,2?-cyclopropylidenebis-[3a,8a]-dihydro-8H-indeno-[1,2-d]-oxazole and (45,4?5,5R,5?R)-2,2?-cyclopropylidenebis-4,5-diphenyldihydro-4,5-oxazole, used as a part of complex catalysts for e.g. stereoselective addition reactions, from the reaction mixtures, by selective sorption of 2,2?-cyclopropylidene-bis(oxazolines) on a sorbent, such as silica gel, isolation of the sorbent from reaction mixture, desorption of 2,2?-cyclopropylidene-bis(oxazolines) from the sorbent with suitable organic solvent and final recovery of 2,2?-cyclopropylidene-bis(oxazolines) from the organic solvent used for desorption process. Catalytic quality of recovered compounds does not differ from those in freshly prepared catalysts.
Abstract: Novel pharmaceutical compositions which contain one of the reverse transcriptase inhibitors, viz., Zidovudine, Lamivudine or Stavudine in clinically efficacious amount and Meldonium as well as pharmaceutically applicable excipients. It has been proved that inclusion of Meldonium in these pharmaceutical compositions essentially diminishes the cardio- and neuro-toxicity of the reverse transcriptase inhibitor.